Regulation of pancreatic cancer therapy resistance by chemokines
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by
high resistance and poor response to chemotherapy. In addition, the poorly immunogenic …
high resistance and poor response to chemotherapy. In addition, the poorly immunogenic …
Molecular mechanisms of pancreatic cancer liver metastasis: the role of PAK2
H Yang, Z Li, S Zhu, W Wang, J Zhang, D Zhao… - Frontiers in …, 2024 - frontiersin.org
Background Pancreatic cancer remains an extremely malignant digestive tract tumor, posing
a significant global public health burden. Patients with pancreatic cancer, once metastasis …
a significant global public health burden. Patients with pancreatic cancer, once metastasis …
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway
X Wang, X Wu, Z Zhang, C Ma, T Wu, S Tang… - Scientific Reports, 2018 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with<
5% five-year survival rate due to late diagnosis, limited treatment options and …
5% five-year survival rate due to late diagnosis, limited treatment options and …
Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells
Y Gao, Z Zhang, K Li, L Gong, Q Yang, X Huang… - Cell death & …, 2017 - nature.com
The acquisition of epithelial–mesenchymal transition (EMT) and/or existence of a sub-
population of cancer stem-like cells (CSC) are associated with malignant behavior and …
population of cancer stem-like cells (CSC) are associated with malignant behavior and …
BRD9-mediated control of the TGF-β/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells
X Wang, C Song, Y Ye, Y Gu, X Li, P Chen… - Nucleic Acids …, 2023 - academic.oup.com
Abstract Bromodomain-containing protein 9 (BRD9) is a specific subunit of the non-
canonical SWI/SNF (ncBAF) chromatin-remodeling complex, whose function in human …
canonical SWI/SNF (ncBAF) chromatin-remodeling complex, whose function in human …
Integrin β1 in pancreatic cancer: expressions, functions, and clinical implications
J Li, L Peng, Q Chen, Z Ye, T Zhao, S Hou, J Gu… - Cancers, 2022 - mdpi.com
Simple Summary Pancreatic cancer (PC) is a highly aggressive malignant tumor with an
extremely poor prognosis. Early diagnosis and treatment are key to improving the survival …
extremely poor prognosis. Early diagnosis and treatment are key to improving the survival …
Myeloid-derived suppressor cells and their role in pancreatic cancer
M Pergamo, G Miller - Cancer gene therapy, 2017 - nature.com
Pancreatic cancer is a devastating disease and ranks as the third most common cause of
cancer-related death. Like many cancers, there has been increased interest in the role of the …
cancer-related death. Like many cancers, there has been increased interest in the role of the …
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
G Xia, H Wang, Z Song, Q Meng, X Huang… - Journal of Experimental & …, 2017 - Springer
Background Pancreatic cancer is susceptible to gemcitabine resistance, and patients
receive less benefit from gemcitabine chemotherapy. Previous studies report that gambogic …
receive less benefit from gemcitabine chemotherapy. Previous studies report that gambogic …
Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress
X Jiang, Y Ma, T Wang, H Zhou, K Wang, W Shi, L Qin… - Gastroenterology, 2023 - Elsevier
Background & Aims Although small patient subsets benefit from current targeted strategies
or immunotherapy, gemcitabine remains the first-line drug for pancreatic cancer (PC) …
or immunotherapy, gemcitabine remains the first-line drug for pancreatic cancer (PC) …
Berberine overcomes gemcitabine-associated chemoresistance through regulation of Rap1/PI3K-Akt signaling in pancreatic ductal adenocarcinoma
K Okuno, C Xu, S Pascual-Sabater, M Tokunaga… - Pharmaceuticals, 2022 - mdpi.com
Gemcitabine (Gem)-based chemotherapy is one of the first-line treatments for pancreatic
ductal adenocarcinoma (PDAC). However, its clinical effect is limited due to development of …
ductal adenocarcinoma (PDAC). However, its clinical effect is limited due to development of …